Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ETX-312
- Development stage
- Preclinical
- Lead developer
- e-Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Administration
- Subcutaneous
01
Overview
ETX-312 is a N-acetyl galactosamine (GalNAc)-conjugated short interfering RNA (siRNA) therapeutic developed by e-Therapeutics. It is designed to treat metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH). The drug operates via RNA interference, silencing a novel and differentiated target gene implicated in MASH pathogenesis. Preclinical studies have demonstrated that ETX-312 significantly improves liver function and reduces disease activity scores in industry-leading diet-induced obesity models of MASH, both as monotherapy and in combination with GLP-1 or THR-beta agonists. The candidate is currently undergoing IND-enabling studies, with an IND submission anticipated in 2025[1][2][4][5][6][8].
- Other names
- ETX 312ETX312ETX-312
Beyond the preview
Go deeper on ETX-312.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ETX-312.